MA53643A - Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 - Google Patents
Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6Info
- Publication number
- MA53643A MA53643A MA053643A MA53643A MA53643A MA 53643 A MA53643 A MA 53643A MA 053643 A MA053643 A MA 053643A MA 53643 A MA53643 A MA 53643A MA 53643 A MA53643 A MA 53643A
- Authority
- MA
- Morocco
- Prior art keywords
- dioxocyclobutenylamino
- picolinamide
- hydroxy
- substituted
- useful
- Prior art date
Links
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 title 1
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 title 1
- -1 N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDE Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734486P | 2018-09-21 | 2018-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53643A true MA53643A (fr) | 2021-12-29 |
Family
ID=68051869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053643A MA53643A (fr) | 2018-09-21 | 2019-09-18 | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10975065B2 (fr) |
| EP (1) | EP3852879A1 (fr) |
| JP (1) | JP6989729B2 (fr) |
| KR (2) | KR102755257B1 (fr) |
| CN (2) | CN116874466A (fr) |
| AR (1) | AR116464A1 (fr) |
| AU (1) | AU2019344107B2 (fr) |
| BR (1) | BR112021003956A2 (fr) |
| CA (1) | CA3055805A1 (fr) |
| CL (1) | CL2021000683A1 (fr) |
| CO (1) | CO2021003391A2 (fr) |
| CR (1) | CR20210146A (fr) |
| CU (1) | CU20210016A7 (fr) |
| DO (1) | DOP2021000045A (fr) |
| EA (1) | EA202190586A1 (fr) |
| EC (1) | ECSP21018584A (fr) |
| GE (2) | GEP20237476B (fr) |
| IL (1) | IL281634B2 (fr) |
| MA (1) | MA53643A (fr) |
| MX (1) | MX2021003318A (fr) |
| MY (1) | MY209296A (fr) |
| NI (1) | NI202100012A (fr) |
| NZ (1) | NZ773473A (fr) |
| PE (1) | PE20211070A1 (fr) |
| PH (1) | PH12021550554A1 (fr) |
| PY (1) | PY1978496A (fr) |
| SG (1) | SG11202101827RA (fr) |
| TW (1) | TWI754172B (fr) |
| UA (1) | UA128700C2 (fr) |
| UY (1) | UY38379A (fr) |
| WO (1) | WO2020058869A1 (fr) |
| ZA (1) | ZA202101169B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20237476B (en) * | 2018-09-21 | 2023-03-27 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |
| BR112022021976A2 (pt) | 2020-04-30 | 2022-12-13 | Idorsia Pharmaceuticals Ltd | Composto, e, composição farmacêutica compreendendo um composto |
| WO2023057548A1 (fr) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur ccr6 |
| EP4423082A1 (fr) | 2021-10-26 | 2024-09-04 | Idorsia Pharmaceuticals Ltd | Modulateurs du récepteur ccr6 |
| KR20240090693A (ko) * | 2021-10-28 | 2024-06-21 | 이도르시아 파마슈티컬스 리미티드 | Ccr6 수용체 조절인자 |
| CN116162081B (zh) * | 2022-12-13 | 2024-08-09 | 药康众拓(江苏)医药科技有限公司 | 一类氘代吡啶酰胺类ccr6抑制剂药物及用途 |
| EP4703354A1 (fr) * | 2023-04-28 | 2026-03-04 | Wuhan Createrna Science and Technology Co.,Ltd. | Composé utilisé comme antagoniste de ccr6, composition pharmaceutique et utilisation associée |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354763A (en) | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| AU686896B2 (en) | 1994-11-16 | 1998-02-12 | American Home Products Corporation | Diaminocyclobutene-3,4-diones |
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| US6495576B2 (en) | 2001-02-07 | 2002-12-17 | Abbott Laboratories | Aminal diones as potassium channel openers |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| PL208928B1 (pl) | 2001-04-16 | 2011-06-30 | Pharmacopeia | 3, 4-di-podstawione cyklobuten-1, 2-diony jako ligandy receptora CXC chemokiny |
| US20040053953A1 (en) | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
| MY139601A (en) * | 2002-10-09 | 2009-10-30 | Schering Corp | Thiadiazoledioxides and thiadiazoleoxides as cxc-and cc-chemokine receptor ligands |
| EP1853583B1 (fr) | 2005-02-16 | 2011-09-07 | Schering Corporation | Pyridyle a liaison amine et piperazine-piperidines substituees a activite agoniste cxcr3 |
| JP2009532380A (ja) | 2006-03-31 | 2009-09-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | カリウムチャンネルのオープナーとしての３，４−ジアミノ−３−シクロブテン−１，２−ジオン誘導体 |
| CN101448778A (zh) | 2006-05-26 | 2009-06-03 | 艾博特公司 | Polo样激酶的抑制剂 |
| AR061829A1 (es) | 2006-07-07 | 2008-09-24 | Schering Corp | Ciclobuten-1, 2-dionas 3,4-di sustituidas como ligandos de receptores de quimiocinas cxc |
| BRPI0810719A8 (pt) | 2007-04-30 | 2016-03-08 | Abbott Lab | Inibidores da enzima diacilglicerol o-acetiltansferase tipo 1 |
| ES2386489T3 (es) | 2007-06-06 | 2012-08-21 | Novartis Ag | Compuestos ciclobutanediona sustituidos anti-inflamatorios |
| WO2009005802A1 (fr) | 2007-07-05 | 2009-01-08 | Schering Corporation | Procédé pour obtenir une taille de cristaux contrôlée dans des composés 3,4-dioxo-1-cyclobutène 1,2-substitués |
| WO2009012375A2 (fr) | 2007-07-19 | 2009-01-22 | Wyeth | Inhibiteurs de la squarate kinase |
| EP2173713B1 (fr) | 2007-07-24 | 2016-02-17 | Bristol-Myers Squibb Company | Dérivés acycliques en tant que modulateurs de l'activité du récepteur de la chimiokine |
| US8536198B2 (en) | 2007-07-24 | 2013-09-17 | Bristol-Myers Squibb Company | Piperidine derivatives as modulators of chemokine receptor activity |
| US20110009482A1 (en) | 2007-12-04 | 2011-01-13 | Schering Corporation | Methods of treating copd |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010063802A1 (fr) | 2008-12-05 | 2010-06-10 | Novartis Ag | Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2 |
| WO2010131145A1 (fr) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Dérivés de cyclobutène-dione |
| PT2473049T (pt) | 2009-09-04 | 2019-03-04 | Sunesis Pharmaceuticals Inc | Inibidores de tirosina quinase de bruton |
| WO2011058027A2 (fr) | 2009-11-12 | 2011-05-19 | F. Hoffmann-La Roche Ag | Composés de purine n-9-substitués, compositions et procédés d'utilisation |
| FR2961695B1 (fr) | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US8648070B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted sulfonamide functionalised phenols as medicaments |
| US8648118B2 (en) | 2010-12-17 | 2014-02-11 | Boehringer Ingelheim International Gmbh | Bicyclic ring system substituted amide functionalised phenols as medicaments |
| MX2014002459A (es) | 2011-08-30 | 2014-04-10 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. |
| FR2981935B1 (fr) | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981936B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| JP2015522546A (ja) | 2012-05-23 | 2015-08-06 | ステマージ バイオテクノロジー エスエー | ミトコンドリア電子伝達鎖の複合体（ｉｉｉ）の活性の阻害剤およびその使用 |
| HK1212348A1 (en) | 2012-12-19 | 2016-06-10 | Novartis Ag | Autotaxin inhibitors |
| EP2948434B1 (fr) | 2013-01-25 | 2017-03-01 | Bristol-Myers Squibb Company | Dérivés squariques pour le traitement de l'hépatite c |
| JP2016518316A (ja) | 2013-03-15 | 2016-06-23 | セルジーン アビロミクス リサーチ， インコーポレイテッド | Ｍｋ２阻害剤およびそれらの使用 |
| FR3030515B1 (fr) | 2014-12-23 | 2017-01-20 | Galderma Res & Dev | Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines |
| MA40886B1 (fr) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| US10660909B2 (en) * | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| GEP20237476B (en) * | 2018-09-21 | 2023-03-27 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |
-
2019
- 2019-09-18 GE GEAP201915588A patent/GEP20237476B/en unknown
- 2019-09-18 EP EP19773556.6A patent/EP3852879A1/fr active Pending
- 2019-09-18 NZ NZ773473A patent/NZ773473A/en unknown
- 2019-09-18 GE GEAP202215588A patent/GEAP202215588A/en unknown
- 2019-09-18 CA CA3055805A patent/CA3055805A1/fr active Pending
- 2019-09-18 CU CU2021000016A patent/CU20210016A7/es unknown
- 2019-09-18 PE PE2021000331A patent/PE20211070A1/es unknown
- 2019-09-18 WO PCT/IB2019/057856 patent/WO2020058869A1/fr not_active Ceased
- 2019-09-18 MY MYPI2021001402A patent/MY209296A/en unknown
- 2019-09-18 KR KR1020237043152A patent/KR102755257B1/ko active Active
- 2019-09-18 CN CN202310857008.9A patent/CN116874466A/zh active Pending
- 2019-09-18 SG SG11202101827RA patent/SG11202101827RA/en unknown
- 2019-09-18 CR CR20210146A patent/CR20210146A/es unknown
- 2019-09-18 MX MX2021003318A patent/MX2021003318A/es unknown
- 2019-09-18 KR KR1020217007932A patent/KR102615234B1/ko active Active
- 2019-09-18 UA UAA202101453A patent/UA128700C2/uk unknown
- 2019-09-18 JP JP2021514571A patent/JP6989729B2/ja active Active
- 2019-09-18 IL IL281634A patent/IL281634B2/en unknown
- 2019-09-18 MA MA053643A patent/MA53643A/fr unknown
- 2019-09-18 AU AU2019344107A patent/AU2019344107B2/en active Active
- 2019-09-18 EA EA202190586A patent/EA202190586A1/ru unknown
- 2019-09-18 BR BR112021003956-2A patent/BR112021003956A2/pt unknown
- 2019-09-18 CN CN201980058547.8A patent/CN112672791B/zh active Active
- 2019-09-19 UY UY0001038379A patent/UY38379A/es not_active Application Discontinuation
- 2019-09-20 PY PY201901978496A patent/PY1978496A/es unknown
- 2019-09-20 TW TW108134010A patent/TWI754172B/zh active
- 2019-09-20 AR ARP190102673A patent/AR116464A1/es unknown
- 2019-09-20 US US16/576,997 patent/US10975065B2/en active Active
-
2021
- 2021-02-22 ZA ZA2021/01169A patent/ZA202101169B/en unknown
- 2021-02-24 NI NI202100012A patent/NI202100012A/es unknown
- 2021-03-05 US US17/192,968 patent/US11708360B2/en active Active
- 2021-03-12 PH PH12021550554A patent/PH12021550554A1/en unknown
- 2021-03-16 CO CONC2021/0003391A patent/CO2021003391A2/es unknown
- 2021-03-16 EC ECSENADI202118584A patent/ECSP21018584A/es unknown
- 2021-03-19 CL CL2021000683A patent/CL2021000683A1/es unknown
- 2021-03-19 DO DO2021000045A patent/DOP2021000045A/es unknown
-
2023
- 2023-05-03 US US18/311,266 patent/US12312344B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| EP3601239A4 (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| EP3687543A4 (fr) | Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv | |
| EP3906026A4 (fr) | Inhibiteurs irréversibles de l'interaction ménine-mll | |
| MA54076A (fr) | 2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8 | |
| MA45189A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA51232A (fr) | Indane-amines utiles en tant qu'antagonistes de pd-l1 | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| EP3906029A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP4013496A4 (fr) | Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire | |
| EP3883570A4 (fr) | Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| FR25C1047I1 (fr) | Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase | |
| MA47086A (fr) | Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| MA53229A (fr) | Amides de diméthyl amino azétidine utilisés en tant qu'inhibiteurs de jak | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| EP3953331A4 (fr) | Pyrazolesulfonamides en tant qu'agents antitumoraux | |
| MA51433A (fr) | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase |